Groups Pained By CMS’ Use Of Coverage With Evidence Development In TENS Proposal
This article was originally published in The Gray Sheet
Executive Summary
A recent Medicare coverage proposal for transcutaneous electrical nerve stimulation for chronic low-back pain is an unprecedented application of CED to turn back coverage of an established treatment, numerous parties tell CMS.
You may also be interested in...
CMS Makes Policy Waves With Pullback Of Longstanding TENS Coverage
The new finalized coverage policy for transcutaneous electrical nerve stimulation for treating chronic back pain is a rare decision by the agency to reverse coverage on an established technology, and is a new direction for the coverage-with-evidence-development program, observers say.
CMS Proposal Would Narrow Longstanding Coverage Of TENS For Back Pain
A CMS coverage proposal on transcutaneous electric nerve stimulation is unusual in that it significantly narrows coverage for a treatment long allowed by the Medicare agency. The proposed change was prompted by new evidence that for low back pain, at least, TENS may not be effective.
Superiority Standard? Groups Bristle At CMS’ Transcatheter Valve Trial Proposal
Some worry that a provision in CMS’ proposed national coverage decision for transcatheter aortic valve replacement devices, which restricts coverage for off-label indications to trials designed to show superiority, signals the agency’s intent to play a more active role in dictating trial designs.